Search Results
Managing CAR-T Cell Therapy in the Real World | Yi Lin, MD, PhD | IMS 2023
CAR-T Therapy, CARTITUDE-1 ciltacabtagene autoleucel in RRMM Patients | Yi Lin, MD, PhD | ASCO 2023
Yi Lin, MD, PhD, offers opinion on anti-BCMA CAR-T cell therapy
Yi Lin, MD, PhD, on how anti-BCMA CAR-T cell therapy fits into the treatment of RRMM
Value of MRD status one month after CAR-T therapy in patients with multiple myeloma
Panelists Discuss Access to CAR-T for Patients with Myeloma
Panel Discusses Novel BCMA-Targeted CAR-T Therapies in the Myeloma Pipeline
Real-World CAR-T Outcomes, Use of Ide-cel, Cilta-cel for Myeloma
Multiple myeloma: elranatamab as a single-agent therapy compared to CAR-T therapy
The risk of T-cell malignancies associated with CAR T-cell therapy
Novel prognosis score for survival in patients with aggressive lymphoma treated with CAR-T therapy
Identifying patients at risk of severe inflammatory adverse events following ide-cel treatment
